AI Summary
We reviewed 80 live results for steqeyma (ustekinumab biosimilar) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Immunology and Pharmaceuticals.
Comparison Table
Recommended
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
BAT2206 (Ustekinumab)
Source: Dr. Reddy’s Laboratories
Description
BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis.
Best for
plaque psoriasis, psoriatic arthritis and autoimmune disease treatment
View Details
Rating
Pyzchiva (Ustekinumab)
Source: Samsung Bioepis
Description
Pyzchiva is an immunology biosimilar for the treatment of autoimmune disorders such as Crohn’s disease and psoriasis.
Best for
Crohn’s disease, psoriasis treatment and immunology patients
View Details
Rating
| Compare | Steqeyma (ustekinumab biosimilar) | BAT2206 (Ustekinumab) | Pyzchiva (Ustekinumab) |
|---|---|---|---|
| Source | Celltrion Healthcare | Dr. Reddy’s Laboratories | Samsung Bioepis |
| Description | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). | BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis. | Pyzchiva is an immunology biosimilar for the treatment of autoimmune disorders such as Crohn’s disease and psoriasis. |
| Best for | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users | plaque psoriasis, psoriatic arthritis and autoimmune disease treatment | Crohn’s disease, psoriasis treatment and immunology patients |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Steqeyma (ustekinumab biosimilar) from Celltrion Healthcare."
I picked this because Steqeyma is a recently HSA-approved biosimilar in Singapore that will soon offer enhanced affordability through government drug subsidies.
Share this search
Related Finds